The principal provisions remaining within rationalisation and integration provisions relate to the exit from the tissue engineering operation and the closure of the Andover, Massachusetts endoscopy manufacturing facility see Note 5.
Rationalisation and integration and liability provisions are expected to be substantially utilised withinfive years.
Included within the liability provision is $42m 2005 $75m relating to the declination of insurance coverage for macrotextured knee revisions see Note 32.
In addition $112m 2005 $79m has been provided against trade and other debtors relating to this issue.
DeferredTaxation continued Movements inthe maincomponentsof deferred tax assets and liabilities were as follows: Retirement Benefit Macrotextured Obligation claim Other Total $ million Deferredtax assets: At 1 January 2005..................... 44 54 47 145 Exchange adjustment................... 4 3 7 Charge credit to income currentyear... 11 32 21 Charge to income prioryears.......... 16 16 Credit to equity........................ 5 5 At 31 December 2005.................. 34 54 60 148 Exchange adjustment................... 1 1 Charge to income currentyear......... 5 10 15 Charge to income prioryears.......... 10 10 Acquisitions.......................... 9 9 Charge to equity....................... 5 5 At 31 December 2006.................. 24 54 32 110 The Group has unused tax losses of $20m 2005 $21m available for offset against future profits.
A deferred tax asset has been recognised in respect of $6m 2005 $5m of such losses.
No deferred tax asset has been recognised on the remaining unused tax losses as these are not expected to be realised in the foreseeable future.
